According to the Zhitong Finance App, Kingsley Biotech (01548) announced Legendary Biotech's first quarter results of 2024, with total revenue of US$93.91 million, up 158.67% year on year; common equity holders of the parent company should have accounted for a loss of US$597.93 million, a year-on-year narrowing of 46.66%; loss per share.

According to the announcement, licensing revenue for the period was $12.2 million, including deferred revenue recognition associated with a global licensing agreement signed with Novartis Pharmaceuticals to develop, produce and commercialize LB2102 and other potential CAR-T therapeutics targeting DLL3. Revenue from the partnership was $78.5 million, and the year-on-year increase of $42.2 million was due to an increase in CARVYKTI sales revenue related to the Janssen agreement.